EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cosciens Biopharma's enterprise value is $2.73 Mil.
Cosciens Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.53 Mil. Therefore, Cosciens Biopharma's EV-to-EBITDA for today is -0.49.
The historical rank and industry rank for Cosciens Biopharma's EV-to-EBITDA or its related term are showing as below:
CSCID'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -704.93 Med: 4.79 Max: 51.28
Current: -0.51
During the past 13 years, the highest EV-to-EBITDA of Cosciens Biopharma was 51.28. The lowest was -704.93. And the median was 4.79.
CSCID's EV-to-EBITDA is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 13.095
vs CSCID: -0.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cosciens Biopharma's PE Ratio (TTM) for today is calculated as:
Cosciens Biopharma's share price for today is $7.00.
Cosciens Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cosciens Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCID vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cosciens Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's EV-to-EBITDA falls into.
Cosciens Biopharma's current Enterprise Value is $2.73 Mil.
Cosciens Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCID) has a EV-to-EBITDA of -0.49 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cosciens Biopharma. According to the industry distribution chart, Cosciens Biopharma ranks #999999 out of 390 companies in the Biotechnology industry.
Is Cosciens Biopharma's EV-to-EBITDA too high?
Cosciens Biopharma's current EV-to-EBITDA is -0.49. Based on the distribution chart, Cosciens Biopharma ranks #999999 out of 390 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #999999 out of 390 companies for EV-to-EBITDA. This places Cosciens Biopharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.10, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cosciens Biopharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current EV-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current EV-to-EBITDA is -0.49. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current EV-to-EBITDA is -0.49 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCID) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued.
The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCID:
EV-to-EBITDA: -0.49
GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCID
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCID has been successfully added to your 
